Manhattan West Asset Management LLC Increases Position in Sanofi (NASDAQ:SNY)

Manhattan West Asset Management LLC increased its position in shares of Sanofi (NASDAQ:SNY) by 1.6% during the 4th quarter, Holdings Channel reports. The firm owned 66,977 shares of the company’s stock after acquiring an additional 1,058 shares during the period. Manhattan West Asset Management LLC’s holdings in Sanofi were worth $3,230,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Arkadios Wealth Advisors boosted its stake in Sanofi by 19.0% in the 4th quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock worth $227,000 after purchasing an additional 751 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Sanofi by 7.1% in the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock worth $14,681,000 after buying an additional 16,780 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Sanofi by 20.9% during the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after acquiring an additional 399,301 shares during the last quarter. Kentucky Trust Co bought a new position in shares of Sanofi during the fourth quarter worth $436,000. Finally, World Investment Advisors LLC grew its stake in Sanofi by 1,020.5% during the third quarter. World Investment Advisors LLC now owns 48,430 shares of the company’s stock valued at $2,791,000 after acquiring an additional 44,108 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Finally, The Goldman Sachs Group started coverage on Sanofi in a report on Friday, March 21st. They set a “neutral” rating and a $65.00 price target for the company. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $62.50.

Sanofi Price Performance

SNY stock opened at $51.50 on Friday. Sanofi has a 52 week low of $45.22 and a 52 week high of $60.12. The firm has a market capitalization of $130.10 billion, a P/E ratio of 20.68, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The company has a fifty day simple moving average of $54.97 and a two-hundred day simple moving average of $52.38. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.